MARKET

DNA

DNA

Ginkgo Bioworks Holdings Inc
NYSE

Real-time Quotes | Nasdaq Last Sale

2.515
-0.095
-3.64%
Opening 12:24 06/29 EDT
OPEN
2.590
PREV CLOSE
2.610
HIGH
2.590
LOW
2.430
VOLUME
7.55M
TURNOVER
8.39M
52 WEEK HIGH
15.86
52 WEEK LOW
2.090
MARKET CAP
4.47B
P/E (TTM)
-1.5592
1D
5D
1M
3M
1Y
5Y
How Much Of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Do Insiders Own?
A look at the shareholders of Ginkgo Bioworks Holdings, Inc. ( NYSE:DNA ) can tell us which group is most powerful...
Simply Wall St. · 1d ago
EATV, the World's First Plant-based Innovation ETF, Makes History at The New York Stock Exchange (NYSE: EATV)
EATV (NYSE: EATV), the VegTech™ Plant-based Innovation & Climate ETF, made history on June 23rd, when its advisor, VegTech™ Invest, threw a party at The New York Stock Exchange celebrating the listing of the world's first Plant-based Innovation ETF.
PR Newswire · 2d ago
Why Ginkgo Bioworks Shares Are Rising After Announcement With Partner Cronos Group
Ginkgo Bioworks Holdings Inc (NYSE: DNA) shares are trading higher by 7.63% to $2.68 after the company, and Cronos Group Inc (NASDAQ: CRON), announced the achievement of the third target productivity milestone in their par
Benzinga · 6d ago
BRIEF-Cronos Group And Ginkgo Bioworks Announce Achievement Of Thcv Equity Milestone
BRIEF-Cronos Group And Ginkgo Bioworks Announce Achievement Of Thcv Equity Milestone
Reuters · 06/21 13:46
Cronos, Ginkgo Bioworks achieve third target milestone for cannabinoids
Canadian cannabis company Cronos Group (NASDAQ:CRON) and Ginkgo Bioworks (DNA), a U.S.-based developer of platforms for cell programming announced on Tuesday the achievement of the third target productivity milestone in
Seekingalpha · 06/21 11:57
Cronos Group And Ginkgo Bioworks Achieve Rare Cannabinoid THCV Equity Milestone
Cronos Group Inc. (NASDAQ: CRON) (TSX:CRON) and Ginkgo Bioworks (NYSE: DNA) achieved the third target productivity milestone in their partnership
Benzinga · 06/21 11:31
Cronos Group and Ginkgo Bioworks Announce Achievement of THCV Equity Milestone
TORONTO and BOSTON, June 21, 2022 /PRNewswire/ -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos"), an innovative global cannabinoid company, and Ginkgo Bioworks (NYSE:DNA) ("Ginkgo"), the
Benzinga · 06/21 11:04
Ginkgo Bioworks stock falls 9% amid Jefferies slashing price target
Ginkgo Bioworks (NYSE:DNA) stock fell ~9% on June 16 while Jefferies Financial cut the stock price target (PT) to $4.35, from $11.50. The stock — which is currently trading around $2.3
Seekingalpha · 06/16 15:30
More
No Data
Learn about the latest financial forecast of DNA. Analyze the recent business situations of Ginkgo Bioworks Holdings Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

37.50%Strong Buy
37.50%Buy
12.50%Hold
12.50%Under-perform
0.00%Sell
Analyst Price Target
The average DNA stock price target is 7.41 with a high estimate of 12.00 and a low estimate of 3.000.
High12.00
Average7.41
Low3.000
Current 2.515
EPS
Actual
Estimate
-0.79-0.59-0.40-0.20
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 192
Institutional Holdings: 667.61M
% Owned: 44.85%
Shares Outstanding: 1.78B
TypeInstitutionsShares
Increased
61
116.82M
New
70
18.04M
Decreased
31
344.52M
Sold Out
43
22.24M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
No Data
About DNA
Ginkgo Bioworks Holdings, Inc., formerly Spinning Eagle Acquisition Corp, is engaged in building a platform to program cells. The Company's platform is used to program cells on behalf of its customers. Its cell programs are designed to enable biological production of products such as therapeutics, key food ingredients, and chemicals derived from petroleum. The Company's platform is used to design, write, and debug deoxyribonucleic acid (DNA) code in engineered organisms to execute programs for its customers. The Company’s platform comprises of equipment, robotic automation, software, data pipelines and tools, and standard operating procedures for genetic engineering, fermentation, and analytics, a library of proprietary genetic assets and associated performance data; and developers and operators of the foundry and codebase. It serves industries, including chemicals, agriculture, food, consumer products, and pharmaceuticals.

Webull offers kinds of Ginkgo Bioworks Holdings Inc stock information, including NYSE:DNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DNA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DNA stock methods without spending real money on the virtual paper trading platform.